about
Natriuretic peptides for acute heart failureNatriuretic peptides for acute heart failureC-type natriuretic peptide concentrations in the plasma and cerebrospinal fluid of patients with subarachnoid hemorrhageScience review: natriuretic peptides in critical illnessSignaling and distribution of NPR-Bi, the human splice form of the natriuretic peptide receptor type BEvidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptideRegulation of axonal development by natriuretic peptide hormonesBrain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agentIn vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidaNatriuretic peptides in relation to the cardiac innervation and conduction system.Impact of obesity on the expression profile of natriuretic peptide system in a rat experimental model.Natriuretic peptides and acute renal failure.Plasma C-type natriuretic peptide as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndromePrognostic value of circulating amino-terminal pro-C-type natriuretic peptide in critically ill patients.Brain and other natriuretic peptides: molecular aspects.In vitro evaluation of cenderitide-eluting stent I -an antirestenosis and proendothelization approach.Atrial natriuretic peptides: anticancer agents.Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer?In vivo Evaluation of Cenderitide-Eluting Stent (CES) II.Atrial natriuretic peptide and related peptides.Natriuretic peptides in cardiovascular diseases.Overview of emerging pharmacotherapy in chronic heart failure.C-type natriuretic peptide modulates permeability of the blood-brain barrierDiabetic neuropathy and heart failure: role of neuropeptides.Natriuretic peptides: Diagnostic and therapeutic use.The alteration of NTproCNP plasma levels following anaerobic exercise in physically active young men.Comparison of infarct-derived and control ovine cardiac myofibroblasts in culture: response to cytokines and natriuretic peptide receptor expression profiles.Inhibition of L-type Ca2+ current by C-type natriuretic peptide in bullfrog atrial myocytes: an NPR-C-mediated effect.Effects of C-type natriuretic peptide on ionic currents in mouse sinoatrial node: a role for the NPR-C receptor.Intracerebroventricular administration of atrial natriuretic peptide prevents increase of plasma ADH, aldosterone and corticosterone levels in restrained conscious dehydrated rabbits.Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia.Effects of gene knockdown of CNP on ventricular remodeling after myocardial ischemia-reperfusion injury through NPRB/Cgmp signaling pathway in rats.Urodilatin and four cardiac hormones decrease human renal carcinoma cell numbers.A new natriuretic peptide isolated from cardiac atria of trout, Oncorhynchus mykiss.Practical implications of current natriuretic peptide research.Five cardiac hormones decrease the number of human small-cell lung cancer cells.Inhibition of restenosis formation without compromising reendothelialization as a potential solution to thrombosis following angioplasty?
P2860
Q24194433-8573F778-95DC-4398-AC46-497137974423Q24245105-35754BB4-C8A1-48FB-B725-AA0C0A5FC9DFQ24795139-87227846-E10D-41B6-9DC5-E942F0C13740Q24799740-EF868F0A-E889-4EC6-97D9-1CFEC56964B3Q28199112-AA4EFCD1-B5C2-4887-99D1-A6FCE4832A19Q28346393-37CD6147-D816-42CA-A662-46F8631975C9Q30491080-D4D7AFC7-4874-42D8-B422-6D0448C54715Q33573360-5172F2F8-6CCB-4BB7-AFB5-34D67FDB299AQ33804636-23C94E71-3708-492A-BB63-BBE6AD06EE7CQ34845237-94E58A8F-089F-40B3-A5C4-5B820E3C4A13Q34979675-BA3731FB-E11B-4164-9F34-D06C217F36A0Q35169820-C39E24B1-D0DD-4D2B-8FA9-77228044404AQ35219788-F4A24F80-D5C6-4D1C-AF41-F3E9C7B02A26Q35566943-8C53E63C-CAD8-47FA-881F-F55AF1B1C785Q35677302-D12E55E8-0979-44A4-BF06-F087EB546A0AQ36206241-204E2F70-0724-4E01-9401-B3F35DA433E7Q36317199-D03751EF-DFAB-4950-A8D0-267C322FAC09Q36399875-77D3C050-560C-4A81-AC16-59A888566B1BQ36470750-F2765EFE-FAB2-4CEA-8184-C2B55DB33801Q36896608-738E8176-01D9-427E-90D3-CC92B8A59701Q36983817-2868D244-470E-4AFD-A40C-5B1E5C6F1259Q37552943-D9A755FD-D5F8-4D31-82FC-0DF7C9F5AC60Q37695310-FE7358A9-EBCC-41AE-86E8-417BB3C10210Q37914972-68BF94AC-9FBA-43AA-88D6-5B6AE434F01BQ39581832-BE21BE42-E9AB-49DE-B694-DFBA5ED217D8Q42078351-057B7AAB-DE46-43E6-816F-F2AAD5D455F4Q42501431-9D8F8E2C-A6C1-4F39-8C0C-53829C253AF6Q44525850-303C8FCE-87EE-4BFF-AB71-58C5D3910142Q44712594-D36D4CE7-ADE7-48E3-96EF-7FDF8B9B7B09Q45222467-3E0C7968-10DE-4DBD-AA9D-654FB4E53FA5Q47612372-99530D0B-5F98-4E6A-9069-BD0F2DE27C63Q48259695-E3BBAAB4-86C7-4AB0-87CD-936D7CE71135Q48399596-A2A8FDE0-0F23-40BF-A1CC-8716E58BB2A9Q48621138-697DF4ED-EC18-478E-BFC9-B3023A190369Q48624965-3646F371-1BD1-4719-81B3-3118B6E2A13EQ48859720-01ED7AAE-19B6-46D1-A1E9-64DB0CD281EBQ50458420-5CC6BC47-FCE3-4A0A-AE48-DE081D3BDDD4
P2860
description
1996 nî lūn-bûn
@nan
1996 թուականին հրատարակուած գիտական յօդուած
@hyw
1996 թվականին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
C-type natriuretic peptide
@ast
C-type natriuretic peptide
@en
C-type natriuretic peptide
@nl
type
label
C-type natriuretic peptide
@ast
C-type natriuretic peptide
@en
C-type natriuretic peptide
@nl
prefLabel
C-type natriuretic peptide
@ast
C-type natriuretic peptide
@en
C-type natriuretic peptide
@nl
P2093
P1433
P1476
C-type natriuretic peptide
@en
P2093
P304
P356
10.1016/S0196-9781(96)00110-6
P407
P577
1996-01-01T00:00:00Z